Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study

Rosmi Shaji  |  December 17, 2015

(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…

Drug Approvals Top 2014 High, but R&D Returns Still Struggle

Ben Hirschler  |  December 15, 2015

LONDON (Reuters)—The number of new drugs approved in the U.S. this year has already topped last year’s 18-year high, yet large pharmaceutical companies are still struggling to get a decent return on their research dollars. In fact, returns on research and development (R&D) spending by the world’s top drug makers have fallen to just 4.2%,…

Hospital Safety Culture Key to Improving Surgical Results

Megan Brooks  |  December 15, 2015

NEW YORK (Reuters Health)—The “safety culture” of a hospital may be just as important in delivering high-quality surgical patient care as more technical issues like surgeon skill and operating room equipment, according to a new study. “The study supports what many surgeons have known for a long time, and that is that the organizational culture…

Valeant Hires Attorney, Crisis Management Firm as U.S. Scrutiny Mounts

Sarah N. Lynch & David Ingram  |  December 14, 2015

WASHINGTON/NEW YORK (Reuters)—Pharmaceuticals firm Valeant, under mounting pressure from Congress and prosecutors over its drug pricing, has hired an attorney in Washington, D.C., and crisis public relations experts with political connections, according to sources familiar with the matter. The move, confirmed by sources and through documents viewed by Reuters, signals a shift for Valeant Pharmaceuticals,…

Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s

Will Boggs, MD  |  December 13, 2015

NEW YORK (Reuters Health)—Careful use of antibiotics and corticosteroids can substantially improve the safety of autologous hematopoietic stem transplantation (HSCT) in patients with refractory Crohn’s disease (CD), researchers from Spain report. “Autologous HSCT is feasible but it is associated with severe adverse events and even mortality,” Dr. Elena Ricart from Hospital Clinic de Barcelona tells…

Exercise Helps Manage Hip Osteoarthritis Pain

Kathryn Doyle  |  December 12, 2015

(Reuters Health)—Water- or land-based exercise should provide some short-term benefit in pain management for hip osteoarthritis, though there are few well-designed trials testing it, according to a new review. “It is nice to finally have some hip-specific data, as hip and knee osteoarthritis are often grouped together, and it’s almost certain that there are differences…

HealthCare.gov Sign-Ups Exceed Last Year’s Pace

Reuters Staff  |  December 10, 2015

NEW YORK (Reuters)—Enrollment in 2016 individual insurance through the HealthCare.gov website is higher than it was a year ago at this time, with 1 million new customers signed up, U.S. government health officials said on Wednesday. The officials cited the latest enrollment data as a reason for confidence in the long-term stability of HealthCare.gov, which…

Smarter Regulation Can Help Cut Drug Prices, Says EU Agency Head

Ben Hirschler  |  December 10, 2015

LONDON (Reuters)—Europe’s top drug regulator weighed into the medicine pricing debate on Wednesday, arguing a smarter and faster pharmaceutical approval system was needed to help rein in the spiraling cost of new treatments. In exchange for speeding up the approval process, society would expect manufacturers to charge less for innovative medicines, European Medicines Agency (EMA)…

Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Will Boggs, MD  |  December 8, 2015

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) commonly develop skin lesions related to anti-tumor necrosis factor (anti-TNF) medications, according to a retrospective study. “We were most surprised by the relatively high percentage (30%) of patients developing skin problems while being treated with anti-TNF agents,” Dr. Isabelle Cleynen from KU Leuven, Belgium, tells Reuters…

Advocating with You—Grassroots Advocacy: Media Outreach 101

From the College  |  December 8, 2015

Rheumatologists must speak for themselves and their patients, because no one else will speak for us. Advocacy is necessary to educate elected officials and preserve our ability to provide the best care to our patients. One way to reach these officials is through the local media. Here are some tips on how to reach out to reporters, write op-eds and letters, and become a knowledgeable resource for your community…

  • « Previous Page
  • 1
  • …
  • 75
  • 76
  • 77
  • 78
  • 79
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences